![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Elidel |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | topical |
Drug class | immunosuppressant |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | low systemic absorption |
Protein binding | 74%–87% |
Metabolism | Hepatic CYP3A |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.124.895 |
Chemical and physical data | |
Formula | C43H68ClNO11 |
Molar mass | 810.46 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema).
It is available as a topical cream. It was developed and formerly marketed by Novartis under the trade name Elidel.